Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Acurx Pharmaceuticals is set to announce its Q2 2025 earnings on Tuesday, August 12th, with analysts expecting a loss of ($0.10) per share.
• The company recently reported a quarterly loss of ($0.11) per share, exceeding expectations of ($0.14) by $0.03.
• Acurx Pharmaceuticals has seen its stock price increase by 1,746.6%, with current trading at $5.67 after a significant rise from a low of $0.28.

Acurx Pharmaceuticals (NASDAQ:ACXP - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Acurx Pharmaceuticals to post earnings of ($0.10) per share for the quarter.

Acurx Pharmaceuticals (NASDAQ:ACXP - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($2.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.80) by $0.60. On average, analysts expect Acurx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acurx Pharmaceuticals Price Performance

ACXP stock traded down $0.18 during midday trading on Friday, reaching $4.47. 58,498 shares of the stock were exchanged, compared to its average volume of 50,482. The stock has a market capitalization of $6.88 million, a PE ratio of -0.32 and a beta of -1.27. Acurx Pharmaceuticals has a 52 week low of $4.17 and a 52 week high of $47.80. The company has a fifty day moving average price of $8.64 and a 200 day moving average price of $9.68.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Wall Street Zen upgraded Acurx Pharmaceuticals to a "sell" rating in a research report on Saturday. HC Wainwright restated a "buy" rating and set a $160.00 price objective on shares of Acurx Pharmaceuticals in a research report on Thursday, May 15th.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.